A Study of MRG007 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

336

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

December 31, 2030

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

MRG007

MRG007 will be administrated as specified in the protocol.

Trial Locations (1)

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Miracogen Inc.

INDUSTRY

NCT07066657 - A Study of MRG007 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter